Loss of the CDK12/cyclin K complex renders triple‐negative breast cancer and HEK293 cells sensitive to various DNA‐damaging agents, including camptothecin, etoposide, and mitomycin C.43Comprehensive genomic analysis of non‐HRD ovarian cancer has broadened our knowledge of the molecular events relevant to patients who cannot receive olaparib plus bevacizumab treatment, and provides a direction for targeted therapy of these patients. This evidence concerns the gene CDK12 and ovarian cancer.